VERU Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Veru Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerVERU

Market Cap38.4M

Cash RunwayRunway > 12 months

Next Catalyst2027-10

Public Research Snapshot

Veru Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Eravacycline in Complicated Urinary Tract Infections (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
GLP-1	n/a	n/a	Phase 2	Public pipeline row
Eravacycline	Complicated Urinary Tract Infections	n/a	Phase 3	Public pipeline row
Veru-944	Prostate Cancer Metastatic	n/a	Phase 2	Public pipeline row
Enobosarm	Obesity & Overweight \| Mobility Disability \| HOMA-IR	n/a	Phase 2	Public pipeline row
Enobosarm & Abemaciclib Combo	Metastatic Breast Cancer	n/a	Phase 3	Public pipeline row
Sabizabulin	Metastatic Breast Cancer	n/a	Phase 2	Public pipeline row
TBPM-PI-HBr	Complicated Urinary Tract Infection \| Acute Pyelonephritis	Antibiotic	Phase 3	Public pipeline row
40 mg Laninamivir Octanoate	Influenza	n/a	Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2027-10	Enobosarm	Low
Corporate Update	Timing not specified	n/a	Low
Fda Meeting	September 2025	GLP-1	Low
Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00653172	Phase 2	COMPLETED	302	2008-06
NCT01180400	Phase 3	COMPLETED	295	2011-09
NCT01793883	Phase 2	COMPLETED	639	2014-05
NCT02784704	Phase 3	COMPLETED	500	2017-05-08
NCT03032510	Phase 3	COMPLETED	1205	2017-12
NCT03646162	Phase 2	COMPLETED	93	2020-04-30
NCT03788967	Phase 3	COMPLETED	1372	2020-05-20
NCT04842747	Phase 3	COMPLETED	204	2022-07-06

Scientific Context

catalyst_type | Corporate Update
catalyst_type | Data Readout
catalyst_type | Corporate Update
catalyst_type | Data Readout
clinical_stage | Phase 3

Want the full VERU research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.